Corimmun is a startup based in Germany, most recent round Acquired, 2 tracked investors.
Corimmun is a startup based in Germany. Corimmun has been acquired. Brouky records 2 investors associated with the company.
Corimmun was a German drug-developing biotech company focused on novel therapeutics and diagnostics for cardiovascular diseases, including heart failure and arteriosclerosis. Its lead compound, COR-1, was in early clinical development for the treatment of heart failure.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.